JP7868066B2 - 線維症を処置する方法 - Google Patents

線維症を処置する方法

Info

Publication number
JP7868066B2
JP7868066B2 JP2023547328A JP2023547328A JP7868066B2 JP 7868066 B2 JP7868066 B2 JP 7868066B2 JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 7868066 B2 JP7868066 B2 JP 7868066B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
dose
fibrosis
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546536A5 (cg-RX-API-DMAC7.html
JP2023546536A (ja
Inventor
ロス リオス, ミゲル デ
ジョン フッド,
アニータ ディフランチェスコ,
Original Assignee
エンデバー バイオメディシンズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンデバー バイオメディシンズ, インコーポレイテッド filed Critical エンデバー バイオメディシンズ, インコーポレイテッド
Publication of JP2023546536A publication Critical patent/JP2023546536A/ja
Publication of JP2023546536A5 publication Critical patent/JP2023546536A5/ja
Priority to JP2026084780A priority Critical patent/JP2026124900A/ja
Application granted granted Critical
Publication of JP7868066B2 publication Critical patent/JP7868066B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023547328A 2020-10-13 2021-10-13 線維症を処置する方法 Active JP7868066B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026084780A JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026084780A Division JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Publications (3)

Publication Number Publication Date
JP2023546536A JP2023546536A (ja) 2023-11-02
JP2023546536A5 JP2023546536A5 (cg-RX-API-DMAC7.html) 2024-11-14
JP7868066B2 true JP7868066B2 (ja) 2026-06-01

Family

ID=81209448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547328A Active JP7868066B2 (ja) 2020-10-13 2021-10-13 線維症を処置する方法
JP2026084780A Pending JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026084780A Pending JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Country Status (8)

Country Link
US (4) US11628167B2 (cg-RX-API-DMAC7.html)
EP (1) EP4229828A4 (cg-RX-API-DMAC7.html)
JP (2) JP7868066B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230107568A (cg-RX-API-DMAC7.html)
CN (1) CN116349204A (cg-RX-API-DMAC7.html)
AU (1) AU2021360767A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198661A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022081661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
CN120916760A (zh) * 2023-02-28 2025-11-07 奋进生物医药公司 治疗纤维化的方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530705A (ja) 2009-06-19 2012-12-06 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
US20200000784A1 (en) 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (cg-RX-API-DMAC7.html) 1977-06-03 1981-03-07 Pfizer
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
WO2011088404A1 (en) 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9970935B2 (en) * 2014-02-06 2018-05-15 The Brigham And Women's Hospital, Inc. Uses of GLI1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
EP3383912A4 (en) 2015-11-30 2019-11-06 Ignyta, Inc. TOPICAL FORMULATIONS
US20190255042A1 (en) * 2016-11-04 2019-08-22 Impact Therapeutics, Inc Application of hedgehog pathway inhibitor in treating fibrosis diseases
CN112449602A (zh) * 2018-07-19 2021-03-05 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN120916760A (zh) 2023-02-28 2025-11-07 奋进生物医药公司 治疗纤维化的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530705A (ja) 2009-06-19 2012-12-06 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
US20200000784A1 (en) 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Horn, A. et al.,Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis,Annals of the Rheumatic Diseases,2012年,Vol.71, No.5,p.785-789,doi:10.1136/annrheumdis-2011-200883
Ueno, H. et al.,A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors,Investigational New Drugs,2018年,Vol.36, No.4,p.647-656,doi:10.1007/s10637-017-0544-y

Also Published As

Publication number Publication date
US20220265650A1 (en) 2022-08-25
US11628167B2 (en) 2023-04-18
US20240342170A1 (en) 2024-10-17
WO2022081661A1 (en) 2022-04-21
US12295954B2 (en) 2025-05-13
AU2021360767A1 (en) 2023-04-27
US12213974B2 (en) 2025-02-04
JP2023546536A (ja) 2023-11-02
US20250235452A1 (en) 2025-07-24
EP4229828A1 (en) 2023-08-23
JP2026124900A (ja) 2026-07-31
EP4229828A4 (en) 2024-08-28
CA3198661A1 (en) 2022-04-21
CN116349204A (zh) 2023-06-27
KR20230107568A (ko) 2023-07-17
US20230201195A1 (en) 2023-06-29
AU2021360767A9 (en) 2024-02-08

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260520

R150 Certificate of patent or registration of utility model

Ref document number: 7868066

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150